Massimiliano F.
- Country
- Italy
- Department
- Centro Clinico Nemo
Research Overview
- A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Usnoflast in Adults with Amyotrophic Lateral Sclerosis
- Efficacy and Safety of DYNE-101 in Participants with Myotonic Dystrophy Type 1: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Spinal Muscular Atrophy Patients on Stable Nusinersen/Risdiplam Regimen
Data & Insights
Has run more than one trial at 100 of 231 partner sites.
Specializations
Neuromuscular Disorders
This investigator specializes in the treatment of Spinal Muscular Atrophy (SMA), exploring innovative therapeutic approaches for patients already receiving established treatments. Their research extends to studying muscle function enhancement and motor capabilities in neuromuscular conditions.
- Motor function assessment in SMA patients
- Combination therapy approaches
- Novel therapeutic agents for SMA
Inflammatory Neuropathies
The investigator focuses on developing treatments for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Their work involves evaluating novel antibody therapies and maintaining clinical responses in patients currently receiving immunoglobulin treatments.
- CIDP treatment optimization
- Immunological therapy assessment
- Inflammatory neuropathy management
Motor Neuron Disease
Research interests include therapeutic interventions for Amyotrophic Lateral Sclerosis (ALS). The investigator studies various compounds aimed at slowing disease progression and improving functional outcomes in ALS patients.
- ALS disease modification
- Functional disability assessment
- Novel therapeutic compounds
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.